nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2024, 07, v.65 763-768
溃疡性结肠炎中医诊疗指南(2023)
基金项目(Foundation): 国家重点研发计划中医药现代化研究重点专项(2018YFC1705403); 国家中医药管理局高水平中医药重点学科建设项目(zyyzdxk-2023271)
邮箱(Email): lijunxiang1226@163.com;
DOI: 10.13288/j.11-2166/r.2024.07.018
发布时间: 2024-04-01
出版时间: 2024-04-01
移动端阅读
摘要:

<正>溃疡性结肠炎(ulcerative colitis,UC)是世界难治性疾病之一。我国UC的发病率呈逐年升高趋势[1]。与未患UC人群相比,UC患者结直肠癌患病风险可高出2.4倍[2]。目前现代医学常用的治疗药物以氨基水杨酸制剂、糖皮质激素、免疫抑制剂、生物制剂等为主,但以上药物存在疗效不稳定、停药后易复发、长期使用易出现不良反应及药物依赖等问题[3-4]

关键词:
Abstract:

KeyWords:
参考文献

[1]XU L, HE B, SUN Y, et al. Incidence of inflammatory bowel disease in urban China:a nationwide populationbased study[J]. Clin Gastroenterol Hepatol, 2023,21(13):3379-3386.

[2]LE BERRE C, ANANTHAKRISHNAN AN, DANESE S,et al. Ulcerative colitis and Crohn's disease have similar burden and goals for treatment[J]. Clin Gastroenterol Hepatol, 2020, 18(1):14-23.

[3]CHOW DK, LEONG RW, TSOI KK, et al. Long-term follow-up of ulcerative colitis in the Chinese population[J]. Am J Gastroenterol, 2009, 104(3):647-654.

[4]CHUDY-ONWUGAJE KO, CHRISTIAN KE, FARRAYE FA, et al. A state-of-the-art review of new and emerging therapies for the treatment of IBD[J]. Inflamm Bowel Dis, 2019,25(5):820-830.

[5]中国中西医结合学会消化系统疾病专业委员会.溃疡性结肠炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):105-111.

[6]中华中医药学会.溃疡性结肠炎诊疗指南[J].中国中医药现代远程教育,2011,9(10):126-128.

[7]GUYATT GH, OXMAN AD, VIST GE, et al. GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650):924-926.

[8]SCHUNEMANN HJ, BEST D, VIST G, et al. Letters,numbers, symbols and words:how to communicate grades of evidence and recommendations[J]. CMAJ, 2003, 169(7):677-680.

[9]JAESCHKE ROMAN,GUYATTGORDON H.,PHIL DELLINGER,等.意见不一致时的策略:应用GRADE网格对临床实践指南达成共识[J].中国循证医学杂志,2009, 9(7):730-733.

[10]中华医学会消化病学分会炎症性肠病学组,中国炎症性肠病诊疗质量控制评估中心.中国溃疡性结肠炎诊治指南(2023年·西安)[J].中华炎性肠病杂志,2024,8(1):33-58.

[11]SATSANGI J, SILVERBERG MS, VERMEIRE S, et al.The Montreal classification of inflammatory bowel disease:controversies, consensus, and implications[J].Gut, 2006, 55(6):749-753.

[12]TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis:final report on a therapeutic trial[J]. Br Med J,1955, 29(4947):1041-1048.

[13]SCHROEDER KW, TREMAINE WJ, ILSTRUP DM.Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis:A randomized study[J]. N Engl J Med, 1987, 317(26):1625-1629.

[14]TRAVIS SP, SCHNELL D, KRZESKI P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis:the Ulcerative Colitis Endoscopic Index of Severity(UCEIS)[J]. Gut, 2012, 61(4):535-542.

[15]国家卫生健康委员会,国家中医药管理局.关于印发《中医病证分类与代码》和《中医临床诊疗术语》的通知[EB/OL].(2020-11-23)[2022-05-01]. http://www.satcm. gov. cn/yizhengsi/zhengcewenjian/2020-11-23/18461. html.

[16]D'AMICO F, MAGRO F, SIEGMUND B, et al. Disease clearance as a new outcome in ulcerative colitis:a systematic review and expert consensus[J]. Inflamm Bowel Dis, 2023:izad159. doi:10. 1093/ibd/izad159.

[17]PEYRIN-BIROULET L, SANDBORN W, SANDS BE,et al. Selecting therapeutic targets in inflammatory bowel disease(STRIDE):determining therapeutic goals for treat-to-target[J]. Am J Gastroenterol, 2015,110(9):1324-1338.

[18]TURNER D, RICCIUTO A, LEWIS A, et al. STRIDE-Ⅱ:An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)Initiative of the International Organization for the Study of IBD(IOIBD):determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5):1570-1583.

[19]雷晓梅,许洪明,温瑶明,等.芍药汤加减加美沙拉嗪灌肠联合美沙拉嗪口服治疗溃疡性结肠炎临床观察[J].中国肛肠病杂志,2016, 36(9):35-37.

[20]徐建军,季峰,陈建永,等.芍药汤加减治疗慢性溃疡性结肠炎疗效观察[J].浙江中医杂志,2007, 42(6):323-324.

[21]周赟,孙吉,巫亚颖,等.红藤肠安汤治疗溃疡性结肠炎疗效观察[J].中国中医药信息杂志,2015, 22(9):22-25.

[22]薛晔,曹志群,周晓凤,等.中药芪仙苡酱煎口服治疗脾虚湿蕴型溃疡性结肠炎疗效及患者的血清炎症和氧化应激指标变化观察[J].山东医药,2019, 59(33):65-68.

[23]王慧丽,赵高明,贾淑亚.清肠化瘀汤治疗轻中度活动期溃疡性结肠炎疗效评价[J].中医药临床杂志,2019, 31(4):730-732.

[24]马月香,侯凤霞,李洪海.白头翁汤加减联合西药治疗大肠湿热型溃疡性结肠炎疗效观察[J].辽宁中医杂志,2020, 47(1):114-116.

[25]孙晓艳,王锐,吉强,等.白头翁汤加味联合保留灌肠治疗溃疡性结肠炎的临床疗效观察[J].世界中西医结合杂志,2018, 13(3):366-369.

[26]史萍慧,温翔.白头翁汤加减对急性期溃疡性结肠炎患者促炎因子及NF-κB mRNA表达的影响[J].中国中医急症,2017, 26(11):2059-2061.

[27]刘思邈,唐艳萍.清热利湿法治疗大肠湿热证溃疡性结肠炎30例[J].中国中西医结合外科杂志,2012, 18(5):441-444.

[28]郭洪波,罗玉梅,王静波.乌梅汤加减治疗溃疡性结肠炎44例[J].新中医,2007, 39(1):44.

[29]王志斌,陈晨,郭一,等.清肠温中方治疗轻中度溃疡性结肠炎的临床研究[J].中国中西医结合杂志,2018,38(1):15-19.

[30]李莉,张雯.溃结宁方治疗溃疡性结肠炎临床研究[J].湖北中医杂志,2009, 31(6):12-13.

[31]邵启蕙,郭颂铭,董秋安.自拟“溃结2号方”治疗溃疡性结肠炎的临床观察[J].同济大学学报(医学版),2020, 41(1):112-116.

[32]史英,张铁,张鹏,等.结肠止泻汤治疗溃疡性结肠炎脾虚湿阻证的临床研究[J].现代中医药,2019, 39(4):76-80.

[33]马友全,白锋.溃结汤治疗慢性溃疡性结肠炎46例[J].新疆中医药,2005, 23(2):28-29.

[34]马友全,白锋.溃结汤抗溃疡性结肠炎复发的临床研究[J].中国实用医药,2011, 6(16):75-76.

[35]王峰,景姗,曹红艳.“健脾调肝化滞方”联合美沙拉嗪治疗溃疡性结肠炎合并抑郁30例临床研究[J].江苏中医药,2019, 51(12):40-43.

[36]何宗琦,吴本升,文科,等.黄葵敛肠方灌肠治疗远端溃疡性结肠炎临床观察[J].河北中医,2019, 41(6):833-837.

[37]龚雨萍,柳文,马贵同,等.清肠栓治疗溃疡性结肠炎的随机对照研究[J].上海中医药大学学报,2007, 21(6):33-36.

[38]王珍,靳桂春,刘媛,等.榆白缓释栓配合治疗溃疡性结肠炎疗效观察[J].山西中医,2017, 33(1):47-48.

[39]沈洪,朱磊,胡乃中,等.虎地肠溶胶囊联合美沙拉秦肠溶片治疗活动期溃疡性结肠炎多中心、随机对照、双盲双模拟的临床研究[J].中国中西医结合杂志,2019, 39(11):1326-1331.

[40]仝战旗,杨波,童新元,等.复方苦参结肠溶胶囊治疗湿热内蕴型溃疡性结肠炎多中心、随机、双盲、对照研究[J].中国中西医结合杂志,2011, 31(2):172-176.

[41]焦英伟,刘强,余兆惠.复方苦参结肠溶胶囊联合美沙拉嗪对改善溃疡性结肠炎患者生活质量的临床研究[J].山西医药杂志,2019, 48(23):2932-2934.

[42]GONG Y, ZHA Q, LI L, et al. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine:a doubleblinded and randomized study[J]. J Ethnopharmacol,2012, 141(2):592-598.

[43]潘燕,欧阳钦.八味锡类散灌肠对溃疡性结肠炎的治疗作用及其机制研究[J].中国中西医结合杂志,2014, 34(1):27-30.

[44]JOOS S, WILDAU N, KOHNEN R, et al. Acupuncture and moxibustion in the treatment of ulcerative colitis:a randomized controlled study[J]. Scand J Gastroenterol,2006, 41(9):1056-1063.

[45]沈群,郑云硉,陆菁.隔附子饼灸联合美沙拉嗪治疗湿热型溃疡性结肠炎疗效观察[J].上海针灸杂志,2019, 38(4):374-377.

[46]蔡辰蕾.溃结宁膏穴位敷贴治疗溃疡性结肠炎脾肾阳虚证的临床疗效观察及对血清IL-10含量的影响[D].长沙:湖南中医药大学,2015.

基本信息:

DOI:10.13288/j.11-2166/r.2024.07.018

中图分类号:R259

引用信息:

[1]李军祥,唐旭东,王化虹,等.溃疡性结肠炎中医诊疗指南(2023)[J].中医杂志,2024,65(07):763-768.DOI:10.13288/j.11-2166/r.2024.07.018.

基金信息:

国家重点研发计划中医药现代化研究重点专项(2018YFC1705403); 国家中医药管理局高水平中医药重点学科建设项目(zyyzdxk-2023271)

发布时间:

2024-04-01

出版时间:

2024-04-01

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文